Kiniksa Pharmaceuticals announces Phase 2/3 trial for KPL-387, targeting recurrent pericarditis, expected mid-2025. Data available in late 2026. Kiniksa Pharmaceuticals announced that it is set to ...
Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results